The invention generally relates to highly adaptable specialized loaders for loading a broad range of brachytherapy carriers, and more specifically to loaders oriented for precisely and predictably loading specialized tile and gore radionuclide carriers that are highly adaptable in real-time in order to treat diverse tumors typically not well treated with current methodologies.
Tumors in living organisms are highly variable in size, location and their amount of infiltration into normal tissues, the variability of tumors in general make them very difficult to treat with a one-size fits all approach. Furthermore, the extent of tumors and/or void upon debulking are typically not known until presented in the operating room. Thus the options necessary to effectively treat a tumor or tumor bed need to be quite diverse.
Brachytherapy involves placing a radiation source either into or immediately adjacent to a tumor. It provides an effective treatment of cancers of many body sites. Brachytherapy, as a component of multimodality cancer care, provides cost-effective treatment. Brachytherapy may be intracavitary, as in gynecologic malignancies; intraluminal, as in but not limited to esophageal or lung cancers; external surface, as in but not limited to cancers of the skin, or interstitial, as in but not limited to the treatment of various central nervous system tumors as well as extracranial tumors of the head and neck, lung, soft tissue, gynecologic sites, rectum, liver, prostate, penis and skin.
The currently available brachytherapy devices and techniques are lacking in the following areas: 1) the current carriers are unable to easily accommodate anatomically conformal and reproducible brachytherapy doses; 2) do not facilitate real-time dosimetric customization for sparing normal tissue, while delivering effective and safe doses of radiation to tumors; and 3) are not able to incorporate additional therapeutic agents, including chemotherapy, and viral, targeted, and DNA damage repair inhibitors
The present invention addresses the deficiencies associated with current brachytherapy devices for treating highly variable tumors and comprises of novel brachytherapy radioisotope carrier loading systems for providing real-time customized brachytherapy treatment to patients with tumors difficult to control using conventional radiation therapy techniques.
The present invention generally relates to devices and methods for loading a preformed radionuclide carrier in a patient to help cure, slow progression or regrowth, or ameliorate symptoms associated with tumors. And more specifically to a versatile dosimetrically customizable brachytherapy real-time loading system for loading a carrier with a targeted radionuclide dose to specific tissues on or within the human body.
Embodiments of the present invention relate to a specialized loading device designed to enable a medical team to create a radionuclide carrier for each patient and tumor reliably, reproducibly and efficiently.
An embodiment of the present invention includes a device for loading preformed brachytherapy carriers comprising a base with a loading bed, a lid with a loading bed insert, one or more entry loading channels paired with an equal number of exit loading channels; and a loading channel support structure. Preferable embodiments include having the one or more entry loading channels and a loading channel support structure in the base; and the one or more exit loading channels in the lid. Additional embodiments allow for the number of entry and exit loading channel pairs to be from 1, 2, 3, 4 or 5, with 1, 2 or 3 most preferred.
Another embodiment of the present invention includes a device for loading brachytherapy carriers comprising a base and a lid; and wherein the base of a loader functions to guide an initial path of a loading needle for seed placement in a soft carrier; provides dimensional stability to a soft carrier during the loading process; centers the soft carrier left to right within the base during the loading process; and shields the user from excess radiation exposure; additionally, the lid of the loader nests and/or mates with the base to become a fully closed and unit; and the loader functions to guide the final path of the loading needle, entirely through the carrier; provides dimensional stability to the soft carrier during the loading process; maintains the position of the carrier superior-inferiorly within the base during the loading process; positions the carrier front to back within the base during the loading process; and shields the user from excess radiation exposure.
An additional embodiment includes various numbers of paths for passing the needles used to load the carriers. There may be one, two, three, four or five paths for loading needles which extend from a proximal surface of a base, through an interior cavity of the loading device and exits through a distal surface of the lid. 1-3 paths is preferred and 1-2 paths most preferred.
Additional embodiments include an interior cavity formed when the lid is properly placed on the base that is substantially filled when a carrier is placed within the cavity and may be of a fixed dimension specific to the loader which may be selected from any one of; 1×2 cm, 2×2 cm or 3×2 cm; 1×3 cm, 2×3 cm or 3×3 cm 1×4 cm, 2×4 cm or 3×4 cm. Additional ½ cm or ¼ cm dimensions within the above dimensions are also contemplated.
Further embodiments of the present invention include the entry path of the loading needle that is an equal distance from a bottom surface of the loader the exit path of the loading needle is from a bottom surface of the loader. And wherein the entry path is in a horizontal plane with the final path. Additionally, the entry and exit loading paths/channels may be between 1-8 mm from the bottom surface of the loading device, with 1-5 mm preferred, depending on the materials used to construct the loader.
Further embodiments include the ability to change the dimensions of the interior cavity by including loading bed liners or a shortened lid with a tooth feature. The bed liners contemplated are of a specific size to fit within the loading bed and have a specific width to raise a carrier to be loaded in relation to the entry and exit loading channels. One or more bed liners may be used and they may have a preferred thickness of 1 mm.
An embodied tooth feature can be formed for embodiments in which the distal end of the lid is shorter than a distal end of the base. A loading bed tooth is used to mate the distal end of a shortened lid with the loading bed of the base. The tooth contains the one or more exit loading channels; and thus shortens the distance between the entry loading channel and the exit loading channel as compared to a full-length lid which ends adjacent to the distal end of the base. The tooth placement on a lid is selected by the user to provide structural support to a carrier that is shorter than the length of the loader bed.
Still further embodiments of the present invention utilize the positioning of the entry and exit path channels in relation to the loader bed to determine and customize and provide a radionuclide carrier with a precise and predictable dosimetry.
Further uses of the presently embodied include using the loader for loading preformed carriers, either to create prepackaged hot carriers or to load “cold” carriers just prior to use.
Additional embodiments may include shielding of the base and/or lid, sterilizable single use loaders or multi-use loaders for manual or automated loading and wherein the loader is loaded in real-time with one or more radioactive seeds.
Further additional embodiments include real-time visual assistance embodiments such as stamping of tile dimensions in large letters on loader top, color coordination of loader in relation to tile sizes, isotopes used, and seed depths.
Yet further embodiments may include the addition of a locking mechanism for a loader in order to maintain the lid in a closed position until the user purposely disengages the locking mechanisms.
Still further embodiments may include the addition enhanced gripping or texture features for a loader in order to assist with handling a loader in a real-time operating field setting.
A further embodiment includes a device for loading brachytherapy carriers including a base and a lid; and wherein the base of the loader functions to guide an initial path of a loading needle for seed placement in a soft carrier; provides dimensional stability to a soft carrier during the loading process; centers the soft carrier left to right within the base during the loading process; and shields the user from excess radiation exposure. In this embodiment the lid of the loader nests and/or mates with the base to become a fully closed unit; and the loader additionally functions to guide the final path of the loading needle, entirely through the carrier; provides dimensional stability to the soft carrier during the loading process; maintains the position of the carrier superior-inferiorly within the base during the loading process; positions the carrier front to back within the base during the loading process; and shields the user from excess radiation exposure. Additionally, the base has, two initial paths for loading needles which extend from a proximal surface of a base, through an interior cavity of the loading device and exits through a distal surface of the lid; an interior cavity is formed when the lid is properly placed on the base and the interior cavity is substantially filled when a carrier is placed within the cavity. The interior cavity may be a fixed dimension specific to the loader for example, having 2×4 cm interior cavity.
Another embodied device for loading brachytherapy carriers includes a base and a lid. The base of the loader functions to guide an initial path of a loading needle for seed placement in a soft carrier; provides dimensional stability to a soft carrier during the loading process; centers the soft carrier left to right within the base during the loading process; and shields the user from excess radiation exposure. The lid of the loader nests and/or mates with the base to become a fully closed unit; and the loader additionally functions to guide the final path of the loading needle, entirely through the carrier; provides dimensional stability to the soft carrier during the loading process; maintains the position of the carrier superior-inferiorly within the base during the loading process; positions the carrier front to back within the base during the loading process; and shields the user from excess radiation exposure.
Additionally in a contemplated embodiment the base has, two initial paths for loading needles which extend from a proximal surface of a base, through an interior cavity of the loading device and exits through a distal surface of the lid. An interior cavity is formed when the lid is properly placed on the base and the interior cavity is substantially filled when a carrier is placed within the cavity. The interior cavity is of a fixed dimension specific to the loader and the dimensions of the interior cavity may be decreased in depth by the addition of one or more bed liners within the loading bed; and/or may be decreased in width by the utilization of a shortened lid with a tooth feature.
The principles of the present invention will be apparent with reference to the following drawings, in which like reference numerals denote like components:
The principles of the present invention will be apparent with reference to the following drawings, in which like reference numerals denote like components:
Definitions
In order to facilitate an understanding of the systems and methods discussed herein, a number of terms are defined below. The terms defined below, as well as other terms used herein, should be construed to include the provided definitions, the ordinary and customary meaning of the terms, and/or any other implied meaning for the respective terms. Thus, the definitions below do not limit the meaning of these terms, but only provide exemplary definitions.
For the purposes of the present disclosure, Brachytherapy is defined as radiation treatment in which the source of the radiation is placed close to the surface of the body or within the body or a body cavity a short distance from the area being treated.
For the purposes of the present disclosure, Teletherapy is defined as radiation treatment in which the source of the radiation is at a distance from the body.
For the purposes of the present disclosure, High Dose Rate is considered to be defined as the treatment with radiation doses above 12,000 cGy/hr.
For the purposes of the present disclosure, Low Dose Rate is considered to be defined as the treatment with radiation in the dose range of 400-2000 cGy/hr
For the purposes of the present disclosure, High Z Materials are considered to be defined as any element with an atomic number greater than 20, or an alloy containing such materials.
For the purposes of the present disclosure, the term Hot is considered to be a material that is Radioactive and the term Cold is considered to mean a material is low in radioactivity; or not radioactive.
For the purposes of the present disclosure, Dosimetry is defined as the process of measurement and quantitative description of the radiation absorbed dose (rad) in a tissue or organ.
For the purposes of the present disclosure, a Tile Carrier sometimes also referred to as a GammaTile is defined as a type of radionuclide carrier that is planar and maintains a two-dimensional planar geometry when placed in use to treat tumors.
For the purposes of the present disclosure, a Gore Carrier sometimes also referred to as a GammaGore is defined as a type of radionuclide carrier that, while initially planar, will assume a 3-dimensional shape when arranged and placed into an operative cavity or similar space and conform to the treatment environment while maintaining the geometry necessary for an effective implant.
For the purposes of the present disclosure, the term Interstitial is defined as pertaining to parts or interspaces of a tissue.
For the purposes of the present disclosure, the term Tumor: is defined as an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells; which can be benign or malignant.
For the purposes of the present disclosure, the term Malignant is defined as tumors having the potential for or exhibiting the properties of anaplasia, invasiveness, and metastasis.
For the purposes of the present disclosure, the term Cancer is defined as any malignant, cellular tumor.
For the purposes of the present disclosure, the term Chemotherapy is defined as a cancer treatment method that uses chemical agents to inhibit or kill cancer cells.
Illustrative embodiments of the invention are described below. In the interest of clarity, not all features of an actual implementation are described in this specification. It will of course be appreciated that in the development of any such actual embodiment, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which will vary from one implementation to another. Moreover, it will be appreciated that such a development effort might be complex and time-consuming, but would nevertheless be a routine undertaking for those of ordinary skill in the art having the benefit of this disclosure.
Application of Embodied Carriers in Central Nervous System Tumors
Despite meticulous surgical technique, tumors metastatic to the brain or spine often recur at or near the site of resection. This is because it is rarely feasible to resect these tumors with pathologically negative margins, especially in the more eloquent regions or where lesions are adjacent to vascular structures or nerves. Radiation therapy, utilizing an increasingly large variety of techniques, has been shown to be the single most effective adjuvant treatment to help prevent recurrence of malignant brain tumors. Interstitial brachytherapy combined with surgical resection of central nervous system tumors has been in use for several decades. Various types of radioactive sources are inserted under direct visualization during the surgery, as potentially more cost effective and less time-consuming therapy, without compromising outcomes.
Nevertheless, techniques for interstitial brachytherapy (BT) of central nervous system tumors have remained relatively crude. The brachytherapy device and methods embodied in the present disclosure, improve the delivery of radiation by creating a carrier system to create combinations of carriers (tiles and/or gores) each with radioactive sources contained within. These carriers, known as tile carriers or “GammaTiles” (GT's) and gore carriers or “GammaGores” (GG's) can be positioned to fit into operative beds by customizing them to the shape and size of individual operative cavities. The GTs can be tailored to protect sensitive normal structures, such as nerves or normal brain, while delivering desired high doses of radiation to the precise locations at highest risk of recurrence. The GTs may also be used as carriers for short-range radioisotopes emitting beta or alpha particles or for delivery of other therapeutic modalities, including chemotherapeutic agents, viral treatments, targeted therapies, and/or DNA damage repair inhibitors. They may also be designed to contain high Z materials and/or biocompatible spacers to afford significant directionality to the radiation treatment.
Application of Embodied Carriers Outside the Central Nervous System
Brachytherapy has been used to treat many tumors of extracranial sites such as head and neck, lung, soft tissue, gynecologic, rectum, prostate, penis, esophagus, pancreas and skin. Brachytherapy (BT) can be used alone or in combination with external beam radiotherapy and/or surgery. Patient outcomes are critically dependent upon proper patient selection and implantation technique. In general, patients with tumors that are intimately associated with critical normal structures to be preserved such as nerves, vessels, cosmetically apparent areas or visceral organs cannot be completely resected without undue morbidity or mortality. These tumors may be good candidates for BT performed in conjunction with surgical resection. Currently available techniques to produce the reliable source spacing needed for optimal geometry and subsequently radiation dosimetry, require catheters and shielding that are relatively bulky and therefore poorly conforming to the treated area. Consequently, they require considerable capital investment and the presence of a team of experts for effective use; and when preformed intraoperatively must be undertaken in a specially shielded operating room to avoid irradiation of adjacent staff and patients. These shortcomings limit the availability of these therapies to very few centers and compromise outcomes by decreasing tumor control and increasing complications from therapy. The brachytherapy device and methods contemplated in the present disclosure, facilitates achieving optimal radioactive source arrangements for permanent low dose rate (LDR) BT in a user-friendly, readily available and cost-effective manner, by using a carrier system of geometrically customizable carriers (GTs/GGs) to contain radioactive sources to be placed into tumors or tumor beds.
Furthermore, the embodiments of the present disclosure, also enables users to preferentially spare sensitive normal tissue without compromising the ability to deliver high dose radiation customized to both tumor and patient anatomy.
Additional embodiments of the tile and or gore carriers may include the ability of the tile and or gore carriers to deliver other cytotoxic agents, such as chemotherapy drugs or very short range radioactive sources such as Y-90 and alpha particles for placement directly into tumors, while maximally sparing normal tissue.
Illustrative embodiments of the invention are described below. In the interest of brevity, not all features of an actual implementation are described in this specification. It will, of course, be appreciated that in the development of any such actual embodiment, numerous implementation-specific decisions such as compliance with regulatory, system-related, and business-related constraints, which will vary from one implementation to another, must be made to achieve the specific goals. Moreover, such a developmental effort might be complex and time-consuming but with the benefit of this disclosure, would be a routine undertaking for those skilled in the art of radiation therapy.
Carrier Systems
Generally the carrier systems described herein and exemplified in
The carrier systems are designed to: create a carrier which allows for more precise and predictable dosimetry; an improved geometry with a better orientation of seeds to one another especially in the settings of real-time, intraoperative environments; is fully customizable to adjust to size/volume, location, and tumor type; and can provide differential dosing of tumor/tumor bed vs. normal tissues.
The carrier systems embodied are generally made of biocompatible materials known in the art and more specifically may be made of gelatin based or collagen based biocompatible materials.
The present disclosure, contemplates of carrier construction using differential thicknesses of biocompatible materials below and/or above the radiation sources (as shown in
The present carriers may include the use of differential color codes to mark end seeds with higher radiation strength than the middle seeds for improved radiation dose distribution for use with limited size and irregular shape targets.
Additional carriers may include the use of markers (color coded dots, arrows, etc) to indicate proper orientation of the tiles. For example, as seeds have both a long and short axis that may not be readily apparent once in the tile, and tiles may be square, or adjacent to other tiles, “green arrow to green arrow, red arrow to red arrow” could indicate both correct seed orientation, and give another guide to precise line-up during placement.
The carriers may be manufactured in multiple size and shape prefabricated tiles of various shapes and sizes (e.g., 1×1 cm, 2×2 cm, 1×3 cm, 2×3 cm, 1×4 cm); these may be preloaded (hot) with the radioactive seeds, or cold to allow for the radioactive seeds to be placed within the tumor or bed just prior to the procedure, which simplifies manufacture of tile for greater variety of carriers, reduces the waste of unused “hot” carriers, and reduces the radiation exposure of the staff.
Additional carriers may also have an impermeable membrane, bio-compound, high Z material or other barrier, which acts to prevent or impede the migration of the compound(s) or agents from the side(s) of the carrier(s) adjacent to the resected tumor to the antipodal side(s) of the carrier(s)(adjacent to normal tissue) and vice versa to create a differential therapeutic impact on the operative bed vs. adjacent tissues.
Additional carriers may use differential thickness of tissue equivalent material below and/or above the tiles and/or a construction of differing high z materials (or just the seed “tube” built into the tile) to achieve the desired radiation dose delivery or normal tissue sparing targeting.
One problem associated surgeons and oncologists often face when treating a subject include a subject with spherical and semispherical intracranial lesions which are common and thus so are similarly shaped postoperative cavities. Any useful carrier and coverage will need to adapt to this shape while being able to be implanted into the brain, and still maintain “ideal” or nearly ideal geometry. One solution embodied by the present disclosure, includes the creation of two-dimensional gores that act as carriers, and when loaded with seeds and placed in the cavity conform to the three-dimensional environment while maintaining geometry of implant. In addition to the three-dimensional nature of the carrier, the carrier may possess additional possible properties previously mentioned including spacing function, differential thickness, and the possibility of combining with high-z materials for radiation protection. These carriers may also be designed so as to be compatible with placement of adjacent tiles or gammatiles as needed for additional intraoperative flexibility.
Additionally the gore-type carrier may be pre-manufactured in specific dimensions and available in a variety of sizes and/or capable of being trimmed to make smaller or combined to make bigger at time of use. The dimensions decided upon can be customized by the user based upon the tumor/cavity size and characteristics to achieve the necessary geometry.
Although certain design shapes are shown as exemplary products in
The proportions are generally fixed by height, width and length, and set by need to maintain ideal implant geometry of seed spacing. The exact length and width depends upon the cavity size but the gore carrier itself may be pre made and/or pre-sized. The gore-type carrier additionally may have seed location presets.
The carriers of the present disclosure may also provide for the use of a small implantable individual carrier constructed for the localized delivery of radioactive materials such as gamma or beta irradiation or alpha particles along with radiation sensitizing agents and/or radiation damage repair inhibitors on the side(s) of the carrier(s) adjacent to the tumor.
The carriers of the present disclosure may also provide for the use of a small implantable individual carrier constructed for the localized delivery of radioactive materials such as gamma or beta irradiation or alpha particles with or without other radiation protection compounds on the side(s) of the carrier(s) antipodal to the radiation source and/or tissue growth promotion/healing factor compounds on the side(s) of the carrier(s) antipodal to the radiation source.
The general gore designs include petals, flaps, and/or a combination of petals and flaps. The proportions are generally fixed by height, width and length, and set by need to maintain ideal implant geometry of seed spacing. The exact length and width depends upon the cavity size but the gore carrier itself may be pre made and/or pre-sized. The gore-type carrier additionally may have seed location presets. When the gore-type material is similar to the petal flap system found in
Certain embodiments of the systems and methods discussed herein also may include the use of a small implantable individual carrier constructed for the localized delivery of radioactive materials such as gamma or beta irradiation or alpha particles along with chemotherapy agents or tumoricidal/targeted/immunotherapeutic or viral/viral vector agent(s) on the side(s) of the carrier(s) adjacent to the tumor.
Certain embodiments of the systems and methods discussed herein also may include the use of a small implantable individual carrier constructed for the localized delivery of radioactive materials such as gamma or beta irradiation or alpha particles along with radiation sensitizing agents and/or radiation damage repair inhibitors on the side(s) of the carrier(s) adjacent to the tumor.
Certain embodiments of the systems and methods discussed herein also may include the use of a small implantable individual carrier constructed for the localized delivery of radioactive materials such as gamma or beta irradiation or alpha particles along with radiation protection compounds on the side(s) of the carrier(s) antipodal to the radiation source and/or tissue growth promotion/healing factor compounds on the side(s) of the carrier(s) antipodal to the radiation source.
The tiles and or gores in the present disclosure include the adaptability of the carrier system to be isotope specific and manage the radionuclide strength and exposure to users and normal (non-targeted) tissues with a variety of measures including differential thicknesses as shown above, seed-tubes (not shown), shielding materials, or spacing facilitators to place radiolabeled seeds in best place in regards to treatment of target and non-treatment of non-target.
The carriers may be MRI compatible and/or visible on fluoroscopy and CT to facilitate accurate intra- and post-operative assessment.
The small individual implantable tiles and/or gores are designed to be carriers for radioactive seeds used to produce a dosimetrically customizable implant in real time for each patient and tumor.
Radionuclide Seed Loading
Certain embodiments of the systems and methods discussed herein may use a variation of seeds in any carrier in order to provide the best dosimetry for the patient tumor and space. Additionally, the loading strands may include one or more of the same seeds or various combinations of well-known low energy radioactive seeds such as Cs 131, Ir 192, I 125, Pd 103 or others commonly known in the art. The seeds placed within the carriers are generally placed as a therapeutic agent in the form of permanent implants intra-operatively following surgical resection, but there may be instance where implants are interchanged removed or replaced.
In other possible loading carriers (Not shown) the carrier may include an “up” or “top” designation on the side opposite of the target zone surface. The hot seed may be encased in a plastic cartridge and loaded into the device with a colored vicryl or similar thread, such that when the seed is loaded into the appropriate position within the tile only certain thread colors are visible, once the alignment is complete the strings on both sides may be pulled, thus pulling the two halves of the plastic cartridge shielding the hot seed. And thus allowing the unshielded hot seed to reside in its proper position within the tile device.
Loading Devices
The present disclosure, also includes a specialized loading device designed to enable the medical team to create a carrier for each patient and tumor reliably, reproducibly and efficiently.
The embodied loaders can be single or multi-use, sterilizable, and shielded if desired. They are designed to load either standard or high-Z material carriers in an accurate, efficient, and real-time manner. The loaders are of similar designs, dimensionally specific, and each consists of two components, the base and the lid.
The base of the loaders functions to: 1) guide the initial path of the loading needle for seed placement in the carrier; 2) provide dimensional stability to the soft carrier during the loading process; 3) center the carrier left-right within the base during the loading process; and 4) shield the user.
The lid of a contemplated loader function to: 1) guide the final path of the loading needle, entirely through the carrier; 2) provide dimensional stability to the soft carrier during the loading process; 3) position the carrier superior-inferiorly within the base during the loading process; 4) position the carrier front to back within the base during the loading process; and 5) shield the user.
The loader designs of the present disclosure, can be made to accommodate a wide variety of GammaTile and GammaGore dimensions and styles. They are illustrated to accommodate seed-in-suture, but can be easily adapted for loose seeds or other configurations.
When loading a seed in suture a needle longer than the loader is used and pulled through the loader channel holes on the proximal end of the base and the distal of the lid. Once the needle protrudes it is pulled the rest of the way with clamps or a needle-nose plier. For example, if the user uses a 60 mm loader the user would want to use a 70 mm needle to feed through the loader channels and deposit the seeds within the carrier.
When the needle loading apparatus is one such as that described in
Application and Treatment with Customized Radionuclide Carrier Systems
The specialized carriers of the present disclosure may provide for certain precise dimensions to allow the carriers to guide users (neurosurgeons, cardiothoracic surgeons, general surgeons, dermatologists, radiation oncologists, urological surgeons, veterinarians or other qualified providers) in maintaining precise and preplanned dosimetry needed to produce effective and safe outcomes.
The dosimetrically customizable implants of the present disclosure may be used as a means of treating, curing, ameliorating, or slowing the progression of various tumors of the body, including but not limited to; tumors of the central nervous system, head and neck, spine, soft tissues, bone, liver, lung, breast, skin, esophagus, stomach, intestines, colon, rectum, prostate, pancreas, retroperitoneal space, kidney, bladder, pelvis, ovary, cervix, fallopian tubes, uterus, and vagina.
The embodied carrier systems may be used in methods to facilitate intracavitary, intraluminal, interstitial, and external surface brachytherapy used with and without surgical resection of the tumors.
The embodied carrier systems may be used in methods specifically for treating extracranial, interstitial, intra-cavitary, surface or visceral site irradiation treatment of various primary and metastatic tumors.
The custom radionuclide carrier systems of the present disclosure may be used for implantation within the central nervous system and include a radiolabeled implant for interstitial implantation comprising a substantially rigid implantable matrix design to be a carrier for radioactive seeds to produce a dosimetrically customizable implant in real-time for each patient and lesion.
The dosimetrically customizable implants described herein may be used to treat, cure ameliorate or slow-down the progression and thus provide a defense against various brain tumors including but not limited to, meningioma, glioma, metastatic cancer and craniopharyngioma.
The rigid implantable matrix designs may include a design wherein the matrix is an implantable tile. The methods of above with the use of low-energy radioactive seeds Cs 131, Ir 192, I125, Pd 103 or other isotopes to be used intraoperative following surgical resection as a permanent implant.
The types of tumors to be treated include primary, secondary and recurrent tumors involving the central nervous system.
A program/spreadsheet/nomogram to guide planning implants and ordering of seeds/tiles based on preoperative lesion size, shape, location, histology and number may be provided to assist the user when using the present carrier systems.
For each of these tumors/tumor beds there is a high variability of size shape and location but the options for the surgeon with the carriers of the present disclosure, are almost unlimited in creating coverage possibilities with the tiles or gores or a combination of the two.
This invention would also be useful in veterinary oncology, either alone or in combination with surgery. Fractionated radiation therapy is logistically more difficult and costly in animals, which require anesthesia prior to delivery of each fraction. Customizable BT, utilizing this invention, will enable delivery of effective and efficient treatment in properly selected tumors.
Although the invention has been described with reference to the above example, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.
Loading Devices
The present disclosure includes a specialized loading device designed to enable the medical team to create a radionuclide carrier for each patient and tumor reliably, reproducibly and efficiently.
The embodied loaders can be single or multi-use, sterilizable, and shielded if desired. They are designed to load either standard or high-Z material carriers in an accurate, efficient, and real-time manner. The loaders are of similar designs, dimensionally specific, and each consists of two components, the base and the lid.
The loader designs of the present disclosure, can be made to accommodate a wide variety of GammaTile and GammaGore dimensions and styles. They are illustrated to accommodate seed-in-suture, but can be easily adapted for loose seeds or other configurations.
When loading a seed in suture a needle longer than the loader is used and pulled through the loader channel holes on the proximal end of the base and the distal of the lid. Once the needle protrudes it is pulled the rest of the way with clamps or a needle-nose plier. One example is wherein you have a 60 mm loader you would want to use a 70 mm needle to feed through the loader channels and deposit the seeds within the carrier.
Example Loader Systems
The Gamma Tile loader (GT-loader) is conceived as a sterilizable single or multi-use device for manual or automated loading (in real time or for pre-loading) of carriers such as but not limited to GammaTiles (GT) or GammaGores (GG) with radioactive seeds such as 1125, Cs131 or Pd111 or other materials. The loaders may be constructed of metal, plastic or composite material, and manufactured by casting, molding, stamping, forming or 3D printing. Embodiments of the loaders contemplated may include shielding either by way of construction with a high Z material, or with other materials with a sufficient dimension (thickness) to provide the necessary dose attenuation for a user.
Alternative embodiments may remain unshielded, and be made of materials suitable for the purpose including but not limited to tungsten, stainless steel, nylon or plastic.
The embodied Loader device generally has two components, a base and a lid. But each component has multiple and specialized functions when used to load radionuclide carriers.
The Base
In some embodiments, the base has a “bed” or a space into which a preformed radionuclide or brachytherapy carrier (GT or GG) is placed. This bed area is of a fixed dimension specific to the loader, and loaders are contemplated in multiple sizes identified for this purpose by the bed size. Bed sizes contemplated may be almost any dimension that falls between 1 cm×1 cm and 4 cm×4 cm (for example 1×2 cm, 2×3 cm and 3×4 cm).
The base of the loaders may function to: 1) guide the initial path of the loading needle for seed placement in the carrier; 2) provide dimensional stability to the soft carrier during the loading process; 3) center the carrier left-right within the base during the loading process; and 4) shield the user.
The “structure” of the base may include a portion with an internal tunnel of appropriate length and diameter (e.g. 20 mm×1.2 mm) which guides the initial path of the loading needle for accurate seed placement in the carrier; and 2) sufficient material to constrain the carrier in the bed on 4 sides with; 3) exterior dimensions which may vary with the material/construction materials used; and 4) the need for a shielded or unshielded device.
An exemplary base of a loader device 1900 is shown in
The Lid
The lid of a contemplated loader may function to: 1) guide the final path of the loading needle, entirely through the carrier; 2) provide dimensional stability to the soft carrier during the loading process; 3) position the carrier superior-inferiorly within the base during the loading process; 4) position the carrier front to back within the base during the loading process; and/or 5) shield the user.
An additional aspect of the lid is its function as a guide for the terminal path of the loading needle through the specific placement of an opening along its far aspect to accept the tip of the loading needle and thereby assure accurate placement of the seeds. Lids is conceived of as being made of as a set for each standard base so that, as an example, a 1×4 cm base can be used to load a 1×2 cm, 1×3 cm, or 1×4 cm carrier by utilizing a lid of appropriate length.
A further feature of this design is that there is a “tooth” on the end of the less than full length lids which add further stability when loading shorter length carriers.
An exemplary lid of a loader device is shown in
Another loading device which allows for variable customization is shown in
When a needle loading apparatus is used to load the radioactive seeds into the carriers such as that described in
Although the invention has been described with reference to the above example, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.
Other Embodiments
Conditional language, such as, among others, “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements and/or steps. Thus, such conditional language is not generally intended to imply that features, elements and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements and/or steps are included or are to be performed in any particular embodiment.
It should be emphasized that many variations and modifications may be made to the above-described embodiments, the elements of which are to be understood as being among other acceptable examples. All such modifications and variations are intended to be included herein within the scope of this disclosure. The foregoing description details certain embodiments of the invention. It will be appreciated, however, that no matter how detailed the foregoing appears in text, the invention can be practiced in many ways. As is also stated above, the use of particular terminology when describing certain features or aspects of the invention should not be taken to imply that the terminology is being re-defined herein to be restricted to including any specific characteristics of the features or aspects of the invention with which that terminology is associated. The scope of the invention should therefore be construed in accordance with the appended claims and any equivalents thereof.
This application is a continuation of U.S. patent application Ser. No. 15/383,724, filed on Dec. 19, 2016, entitled CUSTOMIZABLE RADIOACTIVE CARRIERS AND LOADING SYSTEM, which is a continuation in part of U.S. patent application Ser. No. 15/227,294, filed on Aug. 3, 2016, entitled APPARATUS FOR LOADING DOSIMETRICALLY CUSTOMIZABLE BRACHTHERAPY CARRIERS, which is a continuation of U.S. patent application Ser. No. 14/605,272, filed on Jan. 26, 2015, now U.S. Pat. No. 9,409,038, entitled APPARATUS FOR LOADING DOSIMETRICALLY CUSTOMIZABLE BRACHYTHERAPY CARRIERS, which is a continuation of U.S. patent application Ser. No. 13/460,809, filed on Apr. 30, 2012, now U.S. Pat. No. 8,939,881, entitled APPARATUS FOR LOADING DOSIMETRICALLY CUSTOMIZABLE BRACHYTHERAPY CARRIERS, which claims the benefit under 35 U.S.C. § 119 of U.S. Provisional Application No. 61/480,304, filed on Apr. 28, 2011. This application is also a continuation in part of U.S. patent application Ser. No. 14/703,244, filed on May 4, 2015, now U.S. Pat. No. 9,545,525 entitled DOSIMETRICALLY CUSTOMIZABLE BRACHYTHERAPY CARRIERS AND METHODS THEREOF IN THE TREATMENT OF TUMORS, which is a continuation of U.S. patent application Ser. No. 13/460,792, filed on Apr. 30, 2012, now U.S. Pat. No. 9,022,915, entitled DOSIMETRICALLY CUSTOMIZABLE BRACHYTHERAPY CARRIERS AND METHODS THEREOF IN THE TREATMENT OF TUMORS, which claims the benefit under 35 U.S.C. § 119 of U.S. Provisional Patent Application Ser. No. 61/480,304, filed Apr. 28, 2011, and entitled DOSIMETRICALLY CUSTOMIZABLE INTERSTITIAL RADIONUCLIDE BRAIN IMPLANTS, CARRIERS AND METHODS THEREOF. The disclosures of the foregoing applications are hereby incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
D244393 | Collica et al. | May 1977 | S |
4509506 | Windorski | Apr 1985 | A |
4706652 | Horowitz | Nov 1987 | A |
4754745 | Horowitz | Jul 1988 | A |
4946435 | Suthanthiran et al. | Aug 1990 | A |
5030195 | Nardi | Jul 1991 | A |
D381080 | Ohata | Jul 1997 | S |
5772574 | Nanko | Jun 1998 | A |
5803895 | Kronholz et al. | Sep 1998 | A |
5840008 | Klein et al. | Nov 1998 | A |
5871708 | Park et al. | Feb 1999 | A |
D408957 | Sandor | Apr 1999 | S |
5967966 | Kronholz et al. | Oct 1999 | A |
5997842 | Chen | Dec 1999 | A |
6017482 | Anders et al. | Jan 2000 | A |
D420452 | Cardy | Feb 2000 | S |
D420745 | Cardy | Feb 2000 | S |
D420746 | Cardy | Feb 2000 | S |
6129670 | Burdette et al. | Oct 2000 | A |
D443061 | Bergstrom et al. | May 2001 | S |
6248057 | Mavity et al. | Jun 2001 | B1 |
6327490 | Spetz | Dec 2001 | B1 |
6358195 | Green et al. | Mar 2002 | B1 |
6360116 | Jackson et al. | Mar 2002 | B1 |
6385477 | Werner et al. | May 2002 | B1 |
6450937 | Mercereau et al. | Sep 2002 | B1 |
6471631 | Slater et al. | Oct 2002 | B1 |
6512943 | Kelcz | Jan 2003 | B1 |
6547816 | O'Foghludha | Apr 2003 | B1 |
6712508 | Nilsson et al. | Mar 2004 | B2 |
D488864 | Fago et al. | Apr 2004 | S |
6787042 | Bond et al. | Sep 2004 | B2 |
7011619 | Lewis | Mar 2006 | B1 |
7118729 | O'Foghludha | Oct 2006 | B1 |
D561896 | Jones | Feb 2008 | S |
D580056 | Orthner | Nov 2008 | S |
D580057 | Ramadani | Nov 2008 | S |
7776310 | Kaplan | Aug 2010 | B2 |
8039790 | Cho et al. | Oct 2011 | B2 |
D657474 | Dona | Apr 2012 | S |
8226539 | Cutrer | Jul 2012 | B2 |
D680649 | Jagger et al. | Apr 2013 | S |
D681210 | Beiriger et al. | Apr 2013 | S |
D681812 | Farris et al. | May 2013 | S |
D681813 | Jagger et al. | May 2013 | S |
D686341 | Nakaji et al. | Jul 2013 | S |
D686744 | Nakaji et al. | Jul 2013 | S |
D686745 | Nakaji et al. | Jul 2013 | S |
D686746 | Nakaji et al. | Jul 2013 | S |
D686747 | Nakaji et al. | Jul 2013 | S |
D686748 | Nakaji et al. | Jul 2013 | S |
D687568 | Nakaji et al. | Aug 2013 | S |
D687966 | Nakaji et al. | Aug 2013 | S |
D687967 | Nakaji et al. | Aug 2013 | S |
8600130 | Eriksson Järliden | Dec 2013 | B2 |
8605966 | Eriksson Järliden | Dec 2013 | B2 |
8825136 | Giller et al. | Sep 2014 | B2 |
8876684 | Nakaji et al. | Nov 2014 | B1 |
8939881 | Nakaji et al. | Jan 2015 | B2 |
8974364 | Nakaji et al. | Mar 2015 | B1 |
9022915 | Nakaji et al. | May 2015 | B2 |
9403033 | Brachman | Aug 2016 | B1 |
9409038 | Nakaji et al. | Aug 2016 | B2 |
9492683 | Brachman et al. | Nov 2016 | B2 |
9526463 | Brachman et al. | Dec 2016 | B2 |
9545525 | Nakaji et al. | Jan 2017 | B2 |
9788909 | Larkin et al. | Oct 2017 | B2 |
9789608 | Itkowitz et al. | Oct 2017 | B2 |
9821174 | Fram et al. | Nov 2017 | B1 |
10080909 | Brachman et al. | Sep 2018 | B2 |
10085699 | Brachman et al. | Oct 2018 | B2 |
10265542 | Brachman et al. | Apr 2019 | B2 |
10350431 | Nakaji et al. | Jul 2019 | B2 |
10888710 | Brachman et al. | Jan 2021 | B1 |
10981018 | Baker et al. | Apr 2021 | B2 |
20010044567 | Zamora et al. | Nov 2001 | A1 |
20020055666 | Hunter | May 2002 | A1 |
20020058854 | Creed et al. | May 2002 | A1 |
20020120174 | Steele, Sr. et al. | Aug 2002 | A1 |
20030045769 | Kalas et al. | Mar 2003 | A1 |
20030088141 | Terwilliger et al. | May 2003 | A1 |
20030109769 | Lowery | Jun 2003 | A1 |
20030113359 | Iyer | Jun 2003 | A1 |
20030130573 | Yu et al. | Jul 2003 | A1 |
20030149329 | O'Foghludha | Aug 2003 | A1 |
20030208096 | Tam | Nov 2003 | A1 |
20040091421 | Aston et al. | May 2004 | A1 |
20040109823 | Kaplan | Jun 2004 | A1 |
20040116767 | Lebovic et al. | Jun 2004 | A1 |
20040242953 | Good | Dec 2004 | A1 |
20050035310 | Drobnik et al. | Feb 2005 | A1 |
20050111621 | Riker et al. | May 2005 | A1 |
20050244045 | Eriksson | Nov 2005 | A1 |
20050267319 | White et al. | Dec 2005 | A1 |
20060015030 | Poulin et al. | Jan 2006 | A1 |
20060063962 | Drobnik et al. | Mar 2006 | A1 |
20060173236 | White et al. | Aug 2006 | A1 |
20060235365 | Terwilliger | Oct 2006 | A1 |
20060253048 | Jones | Nov 2006 | A1 |
20070135673 | Elliott | Jun 2007 | A1 |
20070190761 | Dunkley et al. | Aug 2007 | A1 |
20070225544 | Vance et al. | Sep 2007 | A1 |
20080004714 | Lieberman | Jan 2008 | A1 |
20080009661 | Lamoureux et al. | Jan 2008 | A1 |
20080058580 | Black et al. | Mar 2008 | A1 |
20080146861 | Murphy et al. | Jun 2008 | A1 |
20080221384 | Chi Sing et al. | Sep 2008 | A1 |
20090012347 | Helle | Jan 2009 | A1 |
20090069625 | Helle et al. | Mar 2009 | A1 |
20090131735 | Drobnik et al. | May 2009 | A1 |
20090156880 | Allan et al. | Jun 2009 | A1 |
20090253950 | Rapach et al. | Oct 2009 | A1 |
20090271715 | Tumuluri | Oct 2009 | A1 |
20090275793 | Black et al. | Nov 2009 | A1 |
20100056908 | Giller et al. | Mar 2010 | A1 |
20100200778 | Drobnik et al. | Aug 2010 | A1 |
20100228074 | Drobnik et al. | Sep 2010 | A1 |
20100268015 | Drobnik et al. | Oct 2010 | A1 |
20100288916 | Cho et al. | Nov 2010 | A1 |
20100324353 | Helle | Dec 2010 | A1 |
20110013818 | Eriksson Järliden | Jan 2011 | A1 |
20110206252 | Eriksson Järliden | Aug 2011 | A1 |
20120108882 | Hoedl | May 2012 | A1 |
20120165957 | Everland et al. | Jun 2012 | A1 |
20130102832 | Hoedl et al. | Apr 2013 | A1 |
20130102891 | Binnekamp et al. | Apr 2013 | A1 |
20130131434 | Nakaji et al. | May 2013 | A1 |
20130338423 | Nakaji et al. | Dec 2013 | A1 |
20140275715 | Brachman et al. | Sep 2014 | A1 |
20140296612 | Schwartz | Oct 2014 | A1 |
20140316187 | Nakaji et al. | Oct 2014 | A1 |
20150057487 | Nakaji et al. | Feb 2015 | A1 |
20150140535 | Geri et al. | May 2015 | A1 |
20150157879 | Wu et al. | Jun 2015 | A1 |
20150196778 | Nakaji et al. | Jul 2015 | A1 |
20150321024 | Nakaji et al. | Nov 2015 | A1 |
20150367144 | Flynn et al. | Dec 2015 | A1 |
20160242855 | Fichtinger et al. | Aug 2016 | A1 |
20170021191 | Brachman et al. | Jan 2017 | A1 |
20170120073 | Brachman et al. | May 2017 | A1 |
20170215824 | Brachman et al. | Aug 2017 | A1 |
20170252575 | Nakaji et al. | Sep 2017 | A1 |
20190240504 | Brachman et al. | Aug 2019 | A1 |
20200261740 | Baker et al. | Aug 2020 | A1 |
20210236850 | Baker et al. | Aug 2021 | A1 |
Number | Date | Country |
---|---|---|
11 2013 027841 2 | Apr 2012 | BR |
2835065 | Feb 2018 | CA |
2834559 | Nov 2018 | CA |
3017174 | Jan 2020 | CA |
613 528 | May 1935 | DE |
0 292 630 | Aug 1995 | EP |
0 906 769 | Apr 1999 | EP |
2701803 | Aug 2018 | EP |
3456384 | Mar 2019 | EP |
S52-9424 | Jul 1975 | JP |
H09-028810 | Apr 1997 | JP |
2001-266903 | Sep 2001 | JP |
3095304 | Jul 2003 | JP |
2007-512112 | May 2007 | JP |
2009-515603 | Apr 2009 | JP |
2010-536529 | Dec 2010 | JP |
6365983 | Jul 2018 | JP |
WO 2007106531 | Sep 2007 | WO |
WO 2012100206 | Jul 2012 | WO |
WO 2012149580 | Nov 2012 | WO |
WO 2016171961 | Oct 2016 | WO |
WO 2016179420 | Nov 2016 | WO |
Entry |
---|
Cole, P.D., et al., “A comparative long-term assessment of four soft tissue supplements”. Anesthetic Surg J. 31(6). 674-681, 2011. |
International Search Report; International Application No. PCT/US2012/035907, dated Sep. 26, 2012; 3 pages. |
International Search Report; International Application No. PCT/US2012/035909, dated Aug. 30, 2012; 3 pages. |
Crepeau, R.H., et al., “Image Processing of Imperfect Protein Arrays: Sectioned Crystals and Tubulin Sheets and Rings”. Elec. Microsc. Soc. Amer. Proc. 40:84-87, 1982. |
Crepeau, R.H., et al., “Reconstruction of imperfectly ordered zinc-induced tubulin sheets using cross-correlation and real space averaging”. Ultramicroscopy, 6, 7-18, 1981. |
Dagnew, E., et al., “Management of newly diagnosed single brain metastasis using resection and permanent iodine-125 seeds without initial whole-brain radiotherapy: a two institution experience”. Neurosurg Focus. 15; 22(3):E3, 2007. |
Delaney, T.F., et al., “Intraoperative dural irradiation by customized 192 iridium and 90 Yttrium brachytherapy plaques”. Int. J. Radiat Oncol Biol Phys. 57(1): 239-245, 2003. |
Ewersten, et al., “Biopsy Guided by Real-Time Sonography Fused with MRI: A Phantom Study”, American Journal of Roentgenology. 2008; 190: 1672-1674. 10.2214/AJR.07.2587. |
Gutin, P.H., et al., “A coaxial catheter system for after loading radioactive sources for the interstitial irradiation of brain tumors. Technical note”. J. Neurosurg 56: 734-735, 1982. |
Gutin, P.H., et al., “Brachytherapy of recurrent tumors of the skull base and spine with iodine-125 sources”. Neurosurgery 20:938-945, 1987. |
Hamilton, A.J., et al., “The use of gold foil wrapping for radiation protection of the spinal cord for recurrent tumor therapy”. Int. J. Radiat Oncol Biol Phys. 32(2):507-511, 1995. |
Hilaris, B.S., et al., “Interstitial irradiation for unresectable carcinoma of the lung”. Ann Thoracic Surg; 20:491-500, 1975. |
Hilaris, B.S., et al., “Intraoperative radiotherapy in stage I and II lung cancer”. Semin Surg Oncol. 3:22-32, 1987. |
Huang, K., et al., “Surgical resection and permanent iodine-125 brachytherapy for brain metastases”. J. Neurooncol. 91:83-93, 2009. |
Jenkins, H.P., et al., “Clinical and experimental observations on the use of a gelatin sponge or foam”. Surg 20:124-132, 1946. |
Kneschaurek, P. et al.: “Die Flabmethode Zur Intraoperativen Bestrahlung. Öthe Flab-Method for Intraoperative Radiation Therapy”, Strahlentherapie und Oknologie, Urban Und Vogel, Muenchen, DE, vol. 171, No. 2; Feb. 1, 1995, pp. 61-69, XP000610565, ISSN:0179-7158. |
Marchese, M.J., et al., “A versatile permanent planar implant technique utilizing iodine-125 seeds imbedded in gelfoam”. Int J Radiat Oncol Biol Phys 10:747-751, 1984. |
Murphy, M.K., et al., “Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy”. Med Phy 31(6): 1529-1538, Jun. 2004. |
Nori, D., et al., “Intraoperative brachytherapy using Gelfoam radioactive plaque implants for resected stage III non-small-cell lung cancer with positive margin: A pilot study”. J Surg Oncol. 60:257-261, 1995. |
Parashar, B., et al., “Cesium-131 permanent seed brachytherapy: Dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff”. Brachytherapy. 10:508-511, 2011. |
Patel, S., et al., “Permanent iodine-125 interstitial implants for the treatment of recurrent Glioblastoma Multiforme”. Neurosurgery 46 (5) 1123-1128, 2000. |
Rivard, M.J., “Brachytherapy dosimetry parameters calculated for a 131 Cs source”. Med Phys. 34(2): 754-765, 2007. |
Rogers, C.L., et al., “Surgery and permanent 125-1 seed paraspinal brachytherapy for malignant tumors with spinal cord compression”. Int. J. Radial Oncol Biol Phys. 54(2): 505-513, 2002. |
Wernicke, A.G., et al., “Feasibility and safety of Gliasite brachytherapy in the treatment of CNS tumors following neurosurgical resection”. J. Cancer Res Ther. 6(1), 65-74, Jan.-Mar. 2010. |
CivaSheet; “Precision Therapy Without The Beam”; CivaTech Oncology Inc.; CivaTech; https://civatechoncology.com/professionals/civasheet/2 pages; Accessed on Oct. 2018. |
CivaSheet; “Precision Therapy Without The Beam”; CivaTech Oncology Inc.; CivaTech; https://civatechoncology.com/products-2/products/; 5 pages; Accessed on Oct. 2018. |
Aima, Manik et al.; “Dosimetric Characterization of a New Directional Low-Dose Rate Brachytherapy Source”; Department of Medical Physics; Mar. 11, 2018; 32 pages. |
Rivard, Mark J.; “A Directional Pd Brachytherapy Device: Dosimetric Characterization and Practical Aspects for Clinical Use”; Department of Radiation Oncology; Brachytherapy 16 (2017) pp. 421-432. |
Office Action dated Apr. 2, 2015; European Patent Application No. 12724426.7; 5 pages. |
Office Action dated Oct. 30, 2015; European Patent Application No. 12724426.7; 4 pages. |
Office Action dated Feb. 9, 2016; Japanese Application No. 2014-508190; 7 pages including english translation. |
International Search Report; International Application No. PCT/US2016/031035; filed May 5, 2016; 15 pages; dated Aug. 5, 2016. |
International Search Report and Written Opinion; International Application No. PCT/US2016/027143, filed Apr. 12, 2016; dated Aug. 25, 2016; 7 pages. |
Decision of Rejection dated Feb. 4, 2016, Japanese Patent Application No. 2014-508190 with English Translation; 4 pages. |
Search and Examination Report; Application No. P1140/13; Filed on Oct. 24, 2013 (PCT Apr. 30, 2012); 10 pages. |
Summons to Attend Oral Proceedings dated Aug. 18, 2017; European Application No. 12724426.7; 5 pages. |
Office Action dated Nov. 2, 2017; European Patent Application No. 12724427.5; 4 pages. |
Extended European Search Report; Application No. 18186392.9; dated Jan. 7, 2019; 7 pages. |
Miller, S., et al., “Advances in the virtual reality interstitial brachytherapy system.” Engineering Solutions for the Next Millenium. 1999 IEEE Canadian Conference on Electrical and Computer Engineering (Cat. No. 99TH8411). vol. 1. IEEE, 1999. |
Number | Date | Country | |
---|---|---|---|
20200047001 A1 | Feb 2020 | US |
Number | Date | Country | |
---|---|---|---|
61480304 | Apr 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15383724 | Dec 2016 | US |
Child | 16508781 | US | |
Parent | 14605272 | Jan 2015 | US |
Child | 15227294 | US | |
Parent | 13460809 | Apr 2012 | US |
Child | 14605272 | US | |
Parent | 13460792 | Apr 2012 | US |
Child | 14703244 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15227294 | Aug 2016 | US |
Child | 15383724 | US | |
Parent | 14703244 | May 2015 | US |
Child | 15383724 | US |